Who
Anne Vanlent
Director
Company insider
Files Form 4 as: Director, Trevi Therapeutics; Director, Applied Genetic Technologies; Director, Vaxart; Director, Ocera Therapeutics; Director, Novelion Therapeutics; Director, Aegerion Pharmaceuticals; Director, Traws Pharma; Director, Integra LifeSciences Holdings.
In numbers
- Trades disclosed
- 106
- Buys
- 3
- Sells
- 2
- Bought
- $262K
- Sold
- $257K
- Companies
- 10
- Companies where not an officer
- 9
- First trade
- 3 Jan 2006
- Last trade
- 3 Jun 2026
- Last filed
- 4 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Jun 2026filed 4 Jun 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 3 Jun 2026filed 4 Jun 2026 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 11 Jun 2025filed 13 Jun 2025 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 13 Jun 2024filed 14 Jun 2024 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 28 Jun 2023filed 30 Jun 2023 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 30 Nov 2022filed 1 Dec 2022 | Applied Genetic Technologiesoption or derivative | SEC FORM 4 Code D | —16,000 | filing |
| 30 Nov 2022filed 1 Dec 2022 | Applied Genetic Technologiesoption or derivative | SEC FORM 4 Code D | —8,000 | filing |
| 30 Nov 2022filed 1 Dec 2022 | Applied Genetic Technologiesoption or derivative | SEC FORM 4 Code D | —10,000 | filing |
| 30 Nov 2022filed 1 Dec 2022 | Applied Genetic Technologiesoption or derivative | SEC FORM 4 Code D | —10,000 | filing |
| 30 Nov 2022filed 1 Dec 2022 | Applied Genetic Technologiesoption or derivative | SEC FORM 4 Code D | —10,000 | filing |
| 30 Nov 2022filed 1 Dec 2022 | Applied Genetic Technologiesoption or derivative | SEC FORM 4 Code D | —12,000 | filing |
| 30 Nov 2022filed 1 Dec 2022 | Applied Genetic Technologiesoption or derivative | SEC FORM 4 Code D | —14,000 | filing |
| 23 Jun 2022filed 1 Jul 2022 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 23 Jun 2022filed 23 Jun 2022 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 30 Nov 2021filed 2 Dec 2021 | Applied Genetic Technologiesoption or derivative | SEC FORM 4 Code A | —14,000 at $0.00 | filing |
| 16 Jun 2021filed 17 Jun 2021 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 16 Dec 2020filed 18 Dec 2020 | Applied Genetic Technologiesoption or derivative | SEC FORM 4 Code A | —12,000 at $0.00 | filing |
| 11 Jun 2020filed 15 Jun 2020 | TRVI Trevi Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —14,210 at $0.00 | filing |
| 4 Dec 2019filed 6 Dec 2019 | Applied Genetic Technologiesoption or derivative | SEC FORM 4 Code A | —10,000 at $0.00 | filing |
| 12 Jun 2019filed 14 Jun 2019 | Vaxartoption or derivative · Biotechnology | SEC FORM 4 Code A | —9,000 at $0.00 | filing |
News
Citizens Jmp Has Lowered Expectations for Integra LifeSciences (NASDAQ:IART) Stock PriceIART · themarketsdaily.com · 22 Oct 2026Integra LifeSciences (NASDAQ:IART) Stock Gets Price Target Trim from JPMorgan Chase & Co.IART · dailypolitical.com · 22 Oct 2026FinancialContent - Why Integra LifeSciences (IART) stock is falling todayIART · financialcontent.com · 21 Oct 2026Trevi Therapeutics Announces Oral Presentation Accepted at the CHEST 2026 Annual MeetingTRVI · manilatimes.net · 13 Oct 2026
0 headlines in the last 90 days name Anne Vanlent; 4 articles from the last 14 days about the 2 companies they traded most, at most three about any one of them.